Indications › Polycystic ovary syndrome
GLP‑1 drugs in polycystic ovary syndrome
Which incretin agents are being studied in polycystic ovary syndrome, by whom, and when each trial is due to report. Conditions are grouped from the registry’s own wording, which records the same disease several ways.
- Trials on file
- 28
- Active
- 4
- Results scheduled
- 1
- Molecules studied
- 5
- Sponsors
- 18
No GLP‑1 or incretin drug is FDA-approved for polycystic ovary syndrome. The trials below are studies, not approvals, and most drugs tested in a new condition never get approved for it.
No GLP-1 or incretin drug is approved for polycystic ovary syndrome, so everything below is investigational. Most drugs tested in a new condition never reach approval for it, and a registration is not evidence of benefit. 27 of the 28 trials on file are phase 3 or later — the stage sized for a regulator to act on, against 1 still in early phases. 18 distinct sponsors are involved.
Molecules studied in this indication
dulaglutide · exenatide · liraglutide in this indication · semaglutide · tirzepatide
Results due in this indication
| Est. completion | Drug | Trial | Phase | Participants |
|---|---|---|---|---|
| 2028-12 | tirzepatide | A Clincial Study Testing Tirzepatide on Reproductive Function and Metabolic Health in Women With PCOS Who Are Overweight or Obese NCT07326111 · University of Bonn | P4 | 198 |
Trials on file
All 28 incretin trials recorded in this indication, active first.